ORTEXORTEX News
Tracking NKE? Get live short interest, options flow, and signals on ORTEX.Sign up free →
NK
Earnings PreviewNKE

NKE Options Suggest Growing Confidence, But Bears Circle Before September Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 5 Sept 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

NKE heads into its September 8 earnings report with a striking split in positioning signals — options traders have turned notably bullish, while short sellers have quietly rebuilt to a meaningful level over the past month.

The most counterintuitive signal comes from the options market. Buyers have shifted decisively toward calls ahead of the print, driving the put/call ratio down to 0.72 — more than two standard deviations below its 20-day average of 0.81, and close to the lowest reading of the past year. That is the opposite of defensive hedging. It suggests a cohort of traders is actively positioning for an upside surprise from the September 8 release. This follows the prior quarter's outcome, when the stock gained roughly 3.8% on the day and held another 4.2% through the following week — the clearest recent precedent for a post-earnings pop.

Short interest tells a less reassuring story. Bears have added positions steadily since mid-August, pushing SI to 6.1% of the free float — up 20% versus a month ago and the highest level in the recent data window. That is a meaningful position for a mega-cap consumer name. Since the August 26 note flagged this rebuild, shorts have pulled back slightly (down 3.2% in the latest daily reading), but the one-week direction remains upward at 4.5%. Crucially, the borrow market offers no friction to new shorts: availability runs at over 800% of short interest, meaning lending supply vastly outpaces demand, and cost to borrow is a negligible 0.51%. This is a comfortable, low-cost bet against the stock — not a forced or crowded position.

Analysts have been largely in retreat. JP Morgan moved to Underweight with a $40 target in early August, and Truist downgraded to Hold with a $42 target in late August — both recent enough to frame the consensus mood. The mean Street target is around $50, implying roughly 30% upside from current levels near $38, but the dispersion is extreme: BNP Paribas holds a $23 target while Jefferies and Bernstein remain above $70. That range reflects a genuine structural debate. Bulls point to Nike's dominant athleisure positioning, strong wholesale partnerships, and an EPS surprise percentile that ranks in the 99th percentile of the broader universe — the company has historically beaten estimates convincingly. Bears focus on the ongoing sales-organization rebuild, sluggish top-line recovery, and the drag from retail headwinds that have weighed on the stock through a 39% year-to-date decline. The stock is trading at around 18x earnings — not demanding for Nike historically, but unforgiving if revenue trends disappoint.

Philip Knight's family continues to hold roughly 20% of shares, providing a natural anchor. Among institutional holders, Capital World Investors filed a fresh 13G in August disclosing a 6% stake, a signal that at least one major fundamental buyer is adding at current levels. The September 8 print will test whether Nike's recovery narrative — and particularly any early evidence that the "Rip the Script" marketing push is translating into demand — can bridge the gap between options optimism and the more sceptical posture embedded in short interest.

Stocks in this article

See the live data behind this article on ORTEX.

Open NKE on ORTEX →

How this article was generated

Generated
5 Sept 2026, 04:00
Data as of
5 Sept 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.